Raltegravir (RAL) pharmacokinetics (PK) and safety in HIV-1-exposed neonates at high risk of infection (IMPAACT 1110) | Dr. D. Clarke

International Workshop on HIV & Pediatrics 2016

HIV PCR testing at birth in KwaZulu Natal, South Africa – one year post introduction of the largest neonatal HIV testing programme | Dr. F. Moyo

International Workshop on HIV & Pediatrics 2016

Switching to second-line antiretroviral therapy in HIV-infected children: a CIPHER cohort collaboration global analysis | Dr. R. Goodall

International Workshop on HIV & Pediatrics 2016

Paediatric HIV point of care testing: field evaluation of the performance of Cepheid and Alere qualitative HIV assays in a Soweto academic hospital | Dr. T. Murray

International Workshop on HIV & Pediatrics 2016

Low-Resource Perspective on Adolescent Transition and Research Priorities | Mary-Ann Davies, MBChB, MMed, PhD, FC

International Workshop on HIV & Pediatrics 2016

The global epidemiology of perinatally HIV-infected adolescents: A CIPHER Global Cohort Collaboration analysis | Dr. Amy Slogrove

International Workshop on HIV & Pediatrics 2016

It’s Not Just HIV: Complications and Research Priorities in Care of HIV-Infected Youth | Rashida Ferrand, MBBS, MRCP, MSc, DRM&H

International Workshop on HIV & Pediatrics 2016

Higher retention and viral suppression rates in dedicated adolescent-friendly HIV clinic in South Africa | Brian Zanoni, MD, MPH

International Workshop on HIV & Pediatrics 2016

High-Resource Perspective on Adolescent Transition and Research Priorities | Ali Judd

International Workshop on HIV & Pediatrics 2016

Decreased bone turnover in HIV-infected children on antiretroviral therapy | Dr. S. Shiau

International Workshop on HIV & Pediatrics 2016

Does HIV DNA-PCR testing of HIV-exposed infants at birth reduce follow-up for routine testing at 4-14 weeks of age? | Dr. E. Kalk

International Workshop on HIV & Pediatrics 2016

Impact of birth HIV PCR testing on routine 6-week EID testing in Cape Town, South Africa | Dr. L. Dunning

International Workshop on HIV & Pediatrics 2016

Where have all the children gone? High HIV prevalence in infants attending nutrition and inpatient wards | Dr. C. Kiyaga

International Workshop on HIV & Pediatrics 2016

Outcomes of HIV-exposed infants before and after implementing Option B+ PMTCT guidelines in Kampala, Uganda: a retrospective cohort study | Dr. P. Elyanu

International Workshop on HIV & Pediatrics 2016

Impact of tenofovir-containing triple antiretroviral therapy (ART) on bone mineral density in HIV-infected breastfeeding women in sub-Saharan Africa | Dr. L. Stranix

International Workshop on HIV & Pediatrics 2016

Option B+: Beyond ART – Experience with Retention and Outcomes | Landon Myer

International Workshop on HIV & Pediatrics 2016

The Challenge of Drug-Resistant TB in Children with HIV | Simon Schaaf, MMed, PhD

International Workshop on HIV & Pediatrics 2016

Lung function in HIV-infected South African adolesents on antiretroviral therapy: the Cape Town adolescent antiretroviral cohort | Dr. L. Githinji

International Workshop on HIV & Pediatrics 2016

Neuropsychological performance in African HIV children in a multi-site ARV clinical trial is poorer than non-infected children | Dr. M. Boivin

International Workshop on HIV & Pediatrics 2016

Pediatric HIV Treatment and Prevention: From Then to Now | Peter Mugyenyi, MB ChB, FRCPI, FRCP

International Workshop on HIV & Pediatrics 2016

New WHO Guidelines on Breastfeeding | Nigel Rollins

International Workshop on HIV & Pediatrics 2016

Pediatric Drug Pipeline: New Drugs, New Strategies | Martina Penazzato, MD, DTMH, MSc, PhD

International Workshop on HIV & Pediatrics 2016

Testing at Birth – Update from South Africa | Gayle Sherman

International Workshop on HIV & Pediatrics 2016

Virological response and resistance among HIV-infected children on first-line antiretroviral therapy without routine virological monitoring | Dr. Andrew Prendergast

International Workshop on HIV & Pediatrics 2016